Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2026.Apr.16

News

OBI is featured in the Bioconjugate Insights on Bispecific and Dual-Payload ADC Design Strategies
Focusing on Approaches to Address Tumor Heterogeneity and Drug Resistance

2026.Apr.15

News

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.

2026.Apr.09

News

OBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai
Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design

Read More

2026.Apr.01

Announcement

Announcement of the Final Award of the Rapid Arbitration Initiated by OBI in Delaware, USA Against Biosion

2026.Mar.24

Announcement

Announcement on behalf of Amaran of not Distributing Dividends of 2025

2026.Mar.24

Announcement

Announcement on behalf of Amaran that the BOD resolved to convene the 2026 Annual General Shareholders' Meeting

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Driving Value Transformation Through ADC Innovation

Download PDF

Read More

2025 First Extraordinary General Shareholders’ Meeting

  • 2025.Oct.20 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room
Youtube

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact